Gara Jalqabaatti › Dhibee Seli Sikiilii › Maryland
Qorannoo klinikaalii Dhibee Seli Sikiilii Maryland keessatti
Qorannoo 17 Dhibee Seli Sikiilii f Maryland keessatti hirmaatuu jiru.
Magaalota Maryland keessatti
Takkalaa qorannoo (Ingiliffa)
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
- National Institutes of Health Clinical Center, Bethesda
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin 18 hanga 70 · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT03937817Blood Sampling for Research Related to Sickle Cell Disease
- National Institutes of Health Clinical Center, Bethesda
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin 18 hanga 100 · Saalaa hunda · Haaromfame 29-Ful-2026 · NCT00542230Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling
- National Institutes of Health Clinical Center, Bethesda
Namoota walitti qabaa jiraSadarkaa jalqabaa 1
Umuriin 18 hanga 100 · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT06313398A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
- The Johns Hopkins University School of Medicine, Baltimore
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 12 hanga 100 · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT06439082Dietary Intake and Dietary Behaviors in Adults With Sickle Cell Disease
- National Institutes of Health Clinical Center, Bethesda
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 18 hanga 120 · Saalaa hunda · Haaromfame 18-Ful-2026 · NCT05170412Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
- National Institutes of Health Clinical Center, Bethesda
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 hanga 65 · Saalaa hunda · Haaromfame 17-Ful-2026 · NCT05904093Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell Disease
- National Institutes of Health Clinical Center, Bethesda
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 2 hanga 99 · Saalaa hunda · Haaromfame 11-Ful-2026 · NCT06944067SCD Stem Cell Mobilization and Apheresis Using Motixafortide
- National Heart, Blood and Lung Institute-Cellular and Molecular Therapy Branch, Bethesda
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 08-Ful-2026 · NCT06442761Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
- National Institutes of Health Clinical Center, Bethesda
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 4 hanga 65 · Saalaa hunda · Haaromfame 04-Ful-2026 · NCT07599176Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease
- National Institutes of Health Clinical Center, Bethesda
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 hanga 90 · Saalaa hunda · Haaromfame 24-Hag-2026 · NCT07566494A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
- Local Institution - 0064, Baltimore
Namoota walitti qabaa jiraSadarkaa 1/2Hojjettoota fayyaa simatamoo
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 18-Hag-2026 · NCT06481306ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
- Johns Hopkins University Hemophilia Treatment Center, Baltimore
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin hundi · Saalaa hunda · Haaromfame 17-Hag-2026 · NCT04398628Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
- University of Maryland, Baltimore
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 12 fi ol · Saalaa hunda · Haaromfame 14-Hag-2026 · NCT06699849Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
- Center for Cancer and Blood Disorders, Bethesda
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Hag-2026 · NCT07224360The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
- University of Maryland School of Medicine - Baltimore- Site Number : 8400041, Baltimore
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 10 hanga 65 · Saalaa hunda · Haaromfame 29-Ado-2026 · NCT06975865Cooperative Assessment of Late Effects for SCD Curative Therapies
- Johns Hopkins Hospital, Baltimore
- National Institutes of Health Clinical Center, Bethesda
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 4 hanga 65 · Saalaa hunda · Haaromfame 27-Ado-2026 · NCT05153967Virtual Reality Devices as an Adjunct to Usual Care for Patients With Sickle Cell Disease Experiencing Vaso-Occlusive Crises
- University of Maryland Medical Systems, Baltimore
Namoota walitti qabaa jira
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 24-Mud-2025 · NCT06184126Kanneen ClinicalTrials.gov irraa argaman, daataa 05-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.